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INTRODUCTION 
Systemic Lupus Erythematosus is an autoimmune disease in which 
the cells organs tissues undergo damage by tissue binding antibodies.  
Annual incidence of Systemic Lupus Erythematosus(SLE) is 2.8 per 
1,00,000 in United States and Europe.  Estimates of total number with 
this disease ranges from 20 – 60 per 1,00,000.  More than 80% are 
females.  Male to Female ratio is equal in young and old.  Highest 
incidence is between 20 – 50 years of age.  The frequency of Systemic 
Lupus Erythematosus concordance in monozygotic twin  is 25% and with 
1-2% among dizygotic twins.  
AETIOLOGICAL FACTORS IN SYSTEMIC LUPUS 
ERYTHEMATOSUS (SLE) 
Genetic Factors  
¾ HLA, B8, DR2 DR3 
¾ Inherited Complement deficiencies, C4, null allele  
Environmental Factors: 
¾ UV Light 
¾ Physical and Emotional stress  
¾ Infections 
¾ Female sex harmones 
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Drugs 
Procainamide 
Quinidine 
Hydralazine 
Methyldopa 
Chlorpromazine 
Isoniazid 
FREQUENCY OF CLINICAL FEATURES OF SYSTEMIC LUPUS 
ERYTHEMATOSUS (SLE) 
 INDIAN DATA 
% 
WESTERN DATA 
% 
ARTHRITIS 72 – 92 86 – 94 
ALOPECIA 52 – 80 50 
SKIN RASH 74 – 90 60 
PHOTOSENSITIVITY 10 – 62 33 – 62 
MALAR RASH 37 – 76 72 – 90 
ORAL ULCERS 41 – 61 30 
FEVER 74 – 91 80 
LYMPHADENOPATHY 24 – 47 50 
NEUROPSYCHIATRY 19 – 63 20 – 45 
RENAL 35 – 73 29 – 73 
CARDIAC 10 – 29 20 – 30 
PLEUROPULMONARY 9-54 36 – 57 
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1982 REVISED ACR CRITERIA FOR CLASSIFICATION OF SLE 
1. Facial Erythema (Butterfly Rash) 
2. Discoid Lupus 
3. Photosensitivity 
4. Oral ulcers (Painless) 
5. Arthritis (Non Erosive and involving two or more joints) 
6. Serositis (Pleuritis and Pericarditis) 
7. Renal Disorders (Proteinuria > 0.5 gm/day or 3+ cellular Cast) 
8. Neuropsychiatry 
a. Seizures (other causes ruled out) (or) 
b. Psychosis (Other causes ruled out) 
9. Hematologic disorder 
a. Hemolytic anemia 
b. Leucopenia (< 4000/mm3) 
c. Lymphopenia (< 1500/mm3) 
d. Thrombocytopenia (10000/mm3) 
10. Immulonogic disorder 
a. Anti DNA antibody 
b. Anti Sm antibody 
c. Anti Phospholipid antibody 
d. Anti cardiolipid antibody 
e. Positive Lupus anticoagulant 
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11. Anti nuclear antibody 
         In the absence of other causes for ANA positivity, if four of these 
criteria are present, at any time during the course of diseases, a diagnosis 
of SLE can be made with 95% specificity and 75% sensitivity.    
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AIM OF THE STUDY 
1. To analyse the clinical spectrum of manifestations of Systemic 
Lupus Erythematosus (SLE) patients. 
2. To analyse the initial presentation of Systemic Lupus 
Erythematosus (SLE). 
3. To analyse cumulative presentation of SLE. 
4. To study various system involvement. 
5. To analyse the cause of death of SLE patients. 
6. To correlate the clinical and laboratory investigations. 
7. To compare my study with western data. 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
The term Lupus is Latin for “Wolf”.  This term was attributed to 
13th Century physician Rogerius1.   
The Frenchman Cazenave in 1851 was the first one to apply the 
term Lupus Erythematosus.  Van Hehra, a Viennese Physician Latinized 
the disease in his text book “Atlas of skin diseases”.  In 18722 Moretz  
Kaposi recognized the visceral involvement.  He proposed two types of 
disease. 
1.  The discoid 2.  Disseminated form.  He characterized the 
disseminated form by: 
(a) Subcutaneous Nodule  (b) Arthritis  (c) Lympadenopathy  
(d) Fever (e) Weight loss  (f) Anemia (g) Central Nervous system 
involvement. 
In the 1920s and 1930s, SLE was identified as a distinct clinical 
entity, largely because of work of pathologists.  An example of this was 
the atypical non bacterial endocarditis described by Emmanuel3 Libmann 
and Benjamin Sacks in 1924. 
The renal wire loop lesions and other findings were first described 
in 1934 by George Baecher.  Friedberg, Gross and Wallache recognized 
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for first time that disease could occur with out skin manifestations.  Hack 
and Reinhart were the first to describe the false positive syphilis test in 
SLE. 
In 1948, Hargrares Richmond and Morton4 described “LE Cell” in 
the marrow of SLE patients.  In 1957, an American Physician George 
Frion, applied the indirect fluorescent techniques of Coons to study of 
auto antibodies5.  At about the same time, Deicher, Holman and Kunkol6 
auto antibodies to DNA.  Tann and Kunkel (1956) described anti SM 
antibody7.  The recognition that SLE was familial was reported by 
Leonhardt in 1954 later studied by Shulman and Arnett at Hopkins8. 
EPIDEMIOLOGY OF SLE 
Descriptive epidemiologist studies of SLE have been conducted 
worldwide.  The more extensive data9 are available from Scandinavia 
especially from Sweden and United States. 
In the United States, blacks10 have threefold higher incidence 
prevalence and mortality rates than do caucians. 
Analytic and genetic epidemiology studies suggest a multifactorial 
aetiology of SLE, Polygenic mode of inheritance including role of an 
autosomal dominant auto immune gene, female sex hormones and clinical 
exposures.    
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CLINICAL MANIFESTATIONS OF SLE 
The diagnosis of SLE should be made principally on clinical 
grounds with support of laboratory tests. 
The American College of Rheumatology has designated 11 criteria.  
Presence of (4) or more criteria is mandatory for the diagnosis. 
LATENT LUPUS11 
Patients who fail to meet 4 of the 11 criteria are more appropriately 
called as “Lupus like Syndrome”, incomplete or “Latent Lupus” 
The clinical manifestations are protean.  In order of frequency, they 
are as follows:- 
MUSCULOSKELETAL 
The most common presenting symptom of SLE is arthritis. 
1. ARTHRITIS 
Usually episodic, oligoarticular12, migratory; non erosive, non 
deforming and symmetrical arthropathy.  Multiple joints are involved and 
80 – 95% have tender swollen effusive joints.  PIP/MCP/Knees and 
wrists are commonly involved.  The most frequent musculoskeletal X 
ray13 changes are soft tissue swelling/acralsclerosis and  periarticular 
demineralization. 
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Lupus does not involve the spine.  Joint fluid analysis typically 
shows reduced    white cell count and more mononuclear cells. 
 
SYMMETRICAL ARTHRITIS SLE 
2. AVASCULAR NECROSIS 
¾ 10 – 30% of patients with SLE can have this 
¾ It is polyarticular in 90% of the bone 
¾ AVN is more commonly found in hips/carpal bones of wrist/and 
humeral heads14 
¾ 8% of cases are asymptomatic 
¾ MRI is diagnostic though routine X ray can also be useful. 
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3. SEPTIC ARTHRITIS 
 Should be suspected as a cause of Joint pain whenever there 
is swelling and warmth of a Joint coupled with peripheral 
leucocytosis. 
 Aspiration of joint fluid and culture may be mandatory and 
life saving. 
4. MYOSITIS 
 Can present15 in 3 – 5% of SLE patients. 
 CPK is rarely elevated 
 EMG can be abnormal 
 Varying degrees of Lymphocytic/monocytic and plasma cell 
infiltration can be observed 
 Muscle disease in SLE can also be secondary to corticosteroid 
therapy and antimalarials. 
SYSTEMIC 
Systemic complaints like fever; weight loss and fatigue are often 
the initial complaint in 95% of patients.  Among them fatigue16 is the 
most common and is like chronic influenza.  Weight loss is mostly due to 
malabsorbtion of overlap illness or anorexia of severely debilitated 
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patients with CRF or liver disease and is not due to SLE perse.  Fever17 is 
of low-grade type and rarely exceeds 102ºF.  A temperature of more than 
102 ºF needs infection to be ruled out. 
SKIN MANIFESTATIONS 
The skin lesions in SLE are classified in to those that are Lupus 
specific histologically and those that are Lupus non specific18.  The lupus 
specific lesions are divided into Acute sub acute and chronic. 
LUPUS SPECIFIC LESION 
Acute Lesions 
The most recognized skin manifestation of SLE is butterfly rash, 
which usually presents acutely as an Erythematus, elevated lesion, 
pruritus painful in a malar distribution, commonly precipitated by 
exposure to sunlight.  The rash lasts, from days-weeks.  Its presence 
facilitates the diagnosis of SLE and is commonly accompanied by other 
inflammatory manifestations of disease.  By immuno florescence, the 
classic immune deposits at dermal epidermal junction may be seen.  The 
presence of immune deposits in uninvolved skin in patients with SLE has 
been believed to be helpful in diagnosis.19 
Other acute cutaneous lesions are generalized erythema and bullous 
lesions. 
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ACUTE LE LESION + ORAL ULCER 
SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) 
         SCLE refer to a distinct cutaneous lesion that is non fixed, non 
scarring exacerbating and remitting.  This lesion is intermediate between 
evanescent malar rash of active lupus and chronic lesion of disease which 
usually cause scarring.   These lesions generally occur in sun-exposed 
areas and may be generalized.  The lesion originate as Erythematus 
papule or small plaques with a slight scale, and may evolve further to a 
plaques and scale the papulosquamous variant, which mimics psoriasis or 
lichenplanus or merge and form polycyclic or annular lesions. 
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SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS 
 
SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS 
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SLE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS 
Photo sensitivity  
More than 50% of patients with SLE demonstrate photosensitivity.  
In addition to skin lesion, patients may develop exacerbation of systemic 
disease.  The mechanism of photosensitivity is unknown, but it has been 
suggested that lymphocyte from patients with SLE are sensitive to 360 – 
400 nm light related to clastogenic factor in these cells.20  
 
SLE MALAR RASH 
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SLE ALOPECIA 
 
SLE LICHEN PLANUS 
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CHRONIC LESIONS IN LUPUS 
Discoid lesions are chronic cutaneous lesions that may occur in 
absence of any systemic manifestations, as discoid lupus or may be 
manifestation of SLE.  These lesions often begin as erythematous 
papules.  With scaling that may become thick and adherent with a hypo 
pigmented central area.  As lesions progresses, follicular plugging occurs.  
With development of scarring with central atrophy.  Discoid lesions occur 
in malar area or sun exposed areas.  Lesion in scalp lead to extensive 
permanent alopecia.  Discoid lesion may be localized or generalized.  
Generalized discoid lesion A/W systemic features and serological 
abnormalities. 
RENAL SYSTEM 
Renal involvement is found in ½ to 2/3 of patients with SLE.21  It is 
due to deposition of immune complexes in the mesangium or sub 
epithelial, sub endothelial regions of glomeruli.  
WHO CLASSIFICATION OF LUPUS NEPHRITIS 
Class Pattern Site of immune complex 
deposition 
I Normal None 
II Mesangial Mesangial only 
III Focal and segmental 
proliferative 
Mesangaial, Sub endothelial ± Sub 
epithelial   
IV Diffuse proliferative Mesangial, Sub endothelial, Sub 
epithelial  
V Membranaous Mesangial, Sub epithelial  
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Both diffuse proliferative22 GN and progressive forms of focal 
proliferative Nephritis have poor prognosis.  Membranous nephropathy; 
sclerotic glomeruli, fibrous crescents tubular atrophy; and interstitial 
fibrosis denotes inactive lesion.  Renal involvement can be assessed by 24 
hours urinary protein excretion > 500 mg; Creatinine clearance; complete 
urine examination with urinary cytology to detect the presence of 
RBC/WBC/Hyaline and granules casts in urine called as “Telescoped 
Urine”23 which is indicative of severe nephritis.  Urine cytology score 
         2.0 - without disease 
         6.8 - Mild activity 
         11.0 - Moderate – severe activity  
LUPUS NEPHRITIS 
The incidence of Lupus Nephritis is higher in male patients.24 The 
classification of Lupus Nephritis is primarily histological.  Renal biopsy 
is useful in planning current and near future therapies.   Diffuse 
proliferative glomerulo nephritis is more common in male compared to 
female.25  The presence of anti DNA antibodies and decrease of C3 were 
statistically associated with kidney disease.26  If diffuse proliferative 
glomerulo nephritis  is untreated all patients develop ESRD in 7 years.  
Therefore, aggressive immunosupression is indicated unless damage is 
irreversible. The proportion of male with severe lupus nephritis 
presenting with hypertension and reduced Creatinine clearance massive 
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proteinuria and reduced level of complement leading to end stage renal 
disease was significantly higher compared to females.  Thus, lupus 
nephritis in male is a progressive and severe in comparison to female.25  
CARDIOVASCULAR LUPUS 
Patients with SLE may present with following cardiovascular 
manifestations.26,27 in decreasing order of frequency; Pericarditis 12 – 
47%;  LV dysfuction 4 – 71%; Myocarditis 5 – 10%; valvular disease; 
conduction disturbance 10%; pulmonary hypertension 2 – 9%; systemic 
hypertension 15 – 56%, Coronary atherosclerosis 7 – 9%. 
PERICARDITIS 
Occurs in 12 – 47% of living SLE patients; autopsy studies much 
higher prevalence of pericardial involvement ranging up to 61 – 100%.  It 
is the most common manifestation and may be the first manifestation. 
i. PLEURO PERICARDIAC27 
Pain may be first symptom constrictive Pericarditis and cardiac 
tamponade are rare.  Diagnosis was based on presence of pericardial 
friction rub in 71% diagnostic ECG changes in 33% and evidence of 
pericardial effusion by echo in 50%.  Pericardial fluid is exudative; anti 
DNA low complement may be demonstrated in pericardial fluid. 
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ii. LV DYSFUNCTION 
Echo cardiographic studies show 4 – 71% of SLE patients have 
some degree of LV dysfunction patient may present with gallop rhythm 
new murmur on CCF, X ray chest shows cardiomegaly.  Diagnosis is 
made Echo.28 
iii. MYOCARDITIS 
The clinical recognition of Myocarditis ranges from 3 – 15% .  
Most of time sub clinical.  Patient may present with CCF (or) 
Tachycardia (or) Dyspnea.  Myocarditis should be considered in patients 
with Tachycardia, third heart sound, abnormal ECG those with new 
murmurs, conduction disturbance and in those with CCF.  Diagnosis is 
confirmed by global hypokinesia on Echo confirmed by right ventricular 
endomyocardial biopsy. Immunofluorescence study of endomyocardial 
biopsy show Perivascular deposits of IgG and vascular deposits of C3.  
More recently Ga 67 citrate scintigraphy.29 useful in detection of SLE 
Myocarditis.  Another method is Indium33III antimyosin Fab imaging for 
detection of myocardial involvement. 
iv. VALVULAR HEART DISEASE 
Occurs31 in 25 – 93% of SLE patients mitral and aortic 
regurgitations are the most common.  Stenotic lesions very rare.  
Libmansacks32 described that verrucous endocarditis can affect valve 
leaflets, papillary muscles and mural endocardium.  These valvular 
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vegetations do not involve the line of closure and should not deform the 
valve.  Shearn found that systolic murmurs occurred in 70% of SLE 
patients.  Only 4% of SLE patients can have diastolic murmur.  Trans 
Oesophageal echo cardiogram is modality of choice to detect valvular 
heart disease in SLE. 
v. CONDUCTION DISTURBANCES34 
Approximately 10% adult SLE patients can have conduction 
disturbances.  Sinus Tachycardia is seen in 61 – 100% of patients.  
Arrythmias are found more commonly in SLE patients with Pericarditis 
and Myocarditis. 
vi. CORONARY ARTERITIS 
Rare in SLE.  Angina and myocardial infarction are most common 
clinical presentation.  Serial coronary angiography helpful in diagnosis. 
vii. PULMONARY HYPERTENSION42 
It is unusual in SLE patients unlike in MTCD and scleroderma.  
Various studies show the cumulative frequency of above 2 – 9% 
Pulmonary Hypertension in SLE patients.  It is usually asymptomatic and 
discovered on a screening echo Doppler.  Right heart catheterization is 
reserved for symptomatic patients and to guide therapy.  Ventilation – 
perfusion scanning is done to rule out the possibility of multiple 
pulmonary emboli.  Primary pulmonary Hypertension occurs in patients 
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of SLE with Raynaud’s phenomenon.  Other mechanisms being 
pulmonary vasculitis antiphospholipid antibody syndrome and interstitial 
lung disease. 
viii. SYSTEMIC HYPERTENSION 
Prevalence of systemic hypertension in SLE patients is from 15 – 
56% in various studies.  All patients with hypertension in the series of 
Arms Cruz et al and 86% of those in Estes and Christina series had lupus 
nephritis.  Budman and Steinberg found that systemic hypertension in 
SLE patients in absence of renal disease was associated with usage of 
corticosteroids.  Systemic Hypertension is one of the strongest predictors 
of preterm birth in Lupus pregnancy. 
ix. CORONARY ATHEROSCLEROSIS IN SLE 
Prospective studies show clinical detection of angina and 
myocardial infarction is seen with 7 – 9% of SLE patients.  Cross 
sectional (or) Retrospective studies show exercise induced ischemia in 
11-23% of SLE patients.  Patients usually present in their early 40’s with 
angina; myocardial infarction (or) sudden death.  Coronary angiography 
is the gold standard investigation for this.  Stress ECG lack both 
sensitivity and specificity.  Rest and perfusion myocardial single photo 
emission CT (SPECT) is one of the most sensitive and specific means of 
assessing the presence of atherosclerosis but are expensive.  Magnetic 
resonance angiography can be used. 
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GASTROINTESTINAL TRACT / SLE 
Occurrence of painless ulcers in the nose and mouth is m/c c/f of 
GIT lupus.  Almost 100% of patients develop these at some time in the 
course of their disease.  These ulcer indicate a flare.  Nausea/vomiting is 
found in 30%.  Abdominal pain in SLE patients can result from 
pancreatitis.  Ischemic bowel; perforation (or) mesenteric vascultis.38 and 
intussusception.  Lupus peritonitis 39 is the result of small vessel 
involvement in the bowel serosa/retro peritoneum or due to actual 
perforation of the bowel bacterial peritonitis is quite common in patients 
with Nephrotic syndrome.  Parenchymal liver disease40 is quite 
uncommon but liver function studies may be abnormal secondary to drug 
therapy. Aspirin ingestion41 and rarely with thrombosis secondary to 
Phospholipid syndrome. 
 
SLE ORAL ULCER 
 23
PULMONARY DISEASE AND LUPUS43 
Over 50% of SLE patients can have some form of pleural disease 
in their lifetime.  Simple Pleuritis is the most presentation than exudative 
pleural effusion.  Parenchymal lung involvement can occur less 
commonly and may present as acute pneumonitis with dyspnoea.  
Pleuritic chest pain hypoxemia and patchy infiltrations.  The most 
common cause of pulmonary infiltrate in SLE patients is infection44.  
Hemoptysis and overt pulmonary hemorrhage45 are emergencies in SLE 
patients and can be result of pneumonitis (or) pulmonary hemorrhage.  
Shrinking lung found in X-ray chest in some SLE patients is result of 
recurrent atelectasis and diaphragmatic weakness46.  The most common 
pulmonary function abnormality in lupus is reduced carbon monoxide 
diffusion capacity43. 
 
INTERSTITIAL LUNG DISEASE 
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CENTRAL NERVOUS SYSTEM 
66% of SLE patients manifest neuropsychiatry features35.  
Pathogenesis being thrombosis, vasculitis and non immunogenic in 
nature.  C/F include seizure, psychiatry illness, cranial nerve 
involvement, CVA and peripheral nervous system involvement. 
i. SEIZURES 
It is found in 15 – 20 % of SLE patients.  GTCS is the most 
common form though other types have been reported lupus vasculitis, 
thrombosis, steroid therapy: a concominant metabolic problem like 
Uraemia account for the cause. 
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ii. PSYCHIATRY MANIFESTATIONS36 
50 – 67% of patients with SLE manifest this.  Overt Psychosis is 
seen in 12% of SLE patients.  Usually presents as severe depression and 
sleep disturbance.  Anti ribosomal ‘P’ proteins are present in over 60% of 
patients with SLE related.  Psychosis and can help distinguish these 
patients from steroid psychosis37. 
iii. CRANIAL NERVE INVOLVEMENT 
Occur in 10% of SLE patient.  It may be presenting symptom in 
small number of patients. 
iv. C V A 
Risk of CVA is more during first five year of disease.  The 
incidence is 6.6% during first year. 
v. PERIPHERAL N. SYSTEM 
Peripheral N. System is seen in 3.15% patients of SLE.  It present 
as: 
a. Sensory 
b. Sensory Motor Neuropathy 
c. GBS 
d. Mono neuropathy 
e. Mono neuritis multiplex 
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Spinal fluid pleocytosis and high spinal fluid protein levels (or) 
both are helpful indication oligoclonal bands are seen in SLE CSF. 
CT Brain: MRI, PET scanning can detect infarct and demyelinating 
diseases.  
 
SLE VASCULITIS 
 
SLE VASCULITIS WITH FOOT DROP 
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HEMATOLOGY OF SLE47 
The cellular elements48 of blood and coagulation pathway can be 
affected in SLE.  Anemia occurs in 60 – 70% of patient as anemia of 
chronic disease.  Other types like autoimmune hemolytic anemia is found 
in <10% patients.  Positive coomb’s Test can be found in 20 – 60%.  
Leucopenia of either granulocytopenia (or) Lymphopenia can be found in 
50% SLE patients.  Antibodies directed against the cellular elements at 
any point in their maturation pathway is the cause of it. Immuno 
suppressive treatment reverse the cytopenias.  Thrombocytopenia is 
found in 30 – 50% of SLE patients and is related to either anti platelet 
antibodies/antiphospholipid antibody.  Platelet count can be used as a 
parameter to assess the response to treatment.  Anti clotting factor 
antibodies that are directed most commonly to factor 2, 7, 9, xi and xii.  
Lupus anticoagulants that are associated with mild profoundly raised PTT 
are also found in SLE.  The hypercoagulable state in Lupus patients can 
be due to variety of reasons like present of procoagulant antibodies, 
hereditary deficiency of factor C, S and antithrombin 3. 
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SECONDARY APLS / D.V.T. 
HEMOTOLOGICAL MALIGNANCY49 
There are reports that concern with a viral related etiology such as 
liver and vulval carcinoma are found in excess.  Patient with SLE have ↑ 
risk of Nonhodgkins lymphoma49. 
EYE/SLE 
Eye is not commonly involved.  Episcleritis50. Conjuctivitis are 
found in only 10%.  Iritis optic neuritis papilledma and retinal vein 
occlusion are major problems.  Lupus retinopathy51,52 is common in 
patients with active SLE and those with lupus cerebritis.  Retinopathy 
includes micro aneurysm, cotton wool spots, papilledema and retinal 
vasculitis. 
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PREGNANCY53 AND SLE 
Pregnancy has varied effect on SLE activity.  Fertility rates are 
normal in SLE but spontaneous abortions and still birth are frequent (10-
30%) in patients with LA/ACL.  Disease flare especially during 6th week 
postpartum.  There is increase in pregnancy complications like toxemia 
neonatal lupus IUGR heart block abortion and premature delivery are 
hazard to foetus.  Most patients deliver normal infants is cardiac and renal 
disease is absent and SLE activity is controlled.  Glucocorticoids like 
dexamethasone and betamethasone which are not inactivated by placental 
enzymes must be used to suppress disease activity.  Neonatal lupus 
consist of transient skin rashes and permanent heart block and is due to 
transmission of maternal anti RO across the placenta. 
LABORATORY EVALUATION55 OF SLE: 
The laboratory assist the clinician to: 
1. Obtain additional criteria that complement the history and 
physical examination. 
2. To assess the extent of organ involvement 
3. To obtain a quantifiable parameter to follow evolution of 
disease. 
 30
INITIAL TEST 
Complete blood count, blood biochemistry, ESR, CRP, Urine 
Analysis. 
CBC 
• Anemia of normochromic normocytic occasionally 
hemolytic type 
• Leukopenia Lymphopenia, Thrombocytopenia. 
BLOOD BIOCHEMISTRY 
Serum Creatinine, blood urea, Creatinine clearance to know about 
renal deterioration. 
ESR 
Rise in ESR correlates with disease activity in the absence of 
infection.  Most patients even with quiescent disease have westergren 
ESR of upto 70 mm/hr Higher values > 100 denotes vasculitis and 
infection. 
CRP 
         Persistent mild rise in CRP occurs in SLE with Jaccound’s 
arthropathy.  High CRP > 60 mg/dl is seen in SLE patients during inter 
current infections and in lupus associated Serositis. 
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URINE ANALYSIS 
Urine for 24 hrs protein estimation > 500 mg/24 hrs. 
 Proteinuria = active disease 
 Urine cytology for hyalin56granular/RBC/WBC casts =  severe 
nephritis 
SPECIFIC TESTS 
ANA 
These tests are best screening tests.  Indirect immuno fluorescent 
assay is the gold standard method.  If the test substrate contains human 
nuclei WIL.2 (or) HEP-2 cells57 more than 95% of Lupus patients will be 
positive.  These test have high sensitivity (97 – 100%) but low specificity 
and predictive value of 10 – 40%.  A positive ANA test is not specific for 
SLE.  It can occur in some normal individuals in low titre with aging 
other autoimmune diseases, viral infections. Chronic inflammatory 
processes and by several drugs.  So positive ANA test supports diagnosis 
of SLE but not specific.  A negative test makes the diagnosis unlikely but 
not impossible.  Antibodies to (ds DNA) and to Sm done by fair assay are 
relatively specific for SLE.  Determination of complete antibody profile 
of each patient helps product clinical subsets. 
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COMPLEMENT STUDIES 
Total functional hemolytic complement (CH50) levels are the most 
sensitive measure of complement activation but subjected to lab error.  
Very low levels of CH50 with normal levels of C3 suggest inherited 
deficiency of a compliment component which is highly associated with 
SLE and with ANA negativity.  The CH50 assay is a functional assay but 
can be normal even when one (or) more components are low.  C3/C4 are 
the most widely available but are not functional assays.  CH50 and C4 
tends to fall early before clinical signs of disease activity occurs, where as 
C3 often continues to decline during the height of clinical illness.  In 
patients with active nephritis (or) vasculitis fall in C4 levels are often 
markedly depress than C3.  Normal C3 is more predictive of inactive renal 
disease.  As with anti ds DNA the association of complement levels and 
disease activity.  Varies from patient and has to be assessed on an 
individual basis. 
ANA NEGATIVE SLE58 
The original papers of Gladman et al. Fessel and Maddison et al, 
drew specific attention to the subset of patient with ANA negative lupus.  
This subset is negative for the usual screening test used to diagnose SLE 
but displayed other clinical serological manifestations characteristic of 
disease.  Possible reasons could be laboratory error, prozone phenomenon 
and hidden ANA in the serum. 
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FREQUENCY OF VARIOUS ANTIBODIES IN SLE: 
Autoantibody specificity Frequency % 
Native (Double standard) DNA 40.75% 
Denaturanted  simple standard DNA 60 – 90 
Sm 15 – 35 
Nuclear RNP 30 – 85 
SSA 27 – 60 
SSB 8-50 
Histone (total) 50-90 
Ribosomal RNP (P protein) 12-16 
 
LE CELL TEST14 
         In LE cell test, the patients serum is incubated with normal WBCs.  
If the LE factor, an antibody to whole nucleoprotein is present in patients 
serum it penetrates in to nuclei of some of the normal WBCs and causes 
nuclear damage. The damaged Nuclei being Leucotactic are then 
phagocytosized by some of neutrophils that have escaped damage.  If a 
smear of incubated WBCs is made and stained with Wright stain, the 
phagocytosized nuclear material may be observed within some of 
neutrophils as large round, amorphous, smoky basophlic body of such 
large size that it presses the nucleus of a neutrophils against cell 
membrane.  This represents LE cell. 
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LAB MONITORING OF DISEASE ACTIVITY: 
Hematological manifestations as indicators of Disease activity. 
         Hemolytic Anemia + 
         Leucocytopenia + 
         Thrombocytopenia + 
Renal parameters as indicators of disease activity 
         Hematuria + 
         Polyuria + 
         Cast (WBC, RBC, Tubular) + 
         Proteinuria + 
♦ For monitoring SLE, activity the urinary sediment is more useful 
than creatinine clearance. 
♦ Creatinine clearance is more useful than Creatinine alone. 
AUTO ANTIBODIES 
         Antibodies to ds DNA are useful in assessing disease activity.  The 
association is stronger in nephritis flares than in normal exacerbations.  
Several prospective studies demonstrated increasing anti ds DNA titres 
preceeding clinical flares in 50 – 100% of cases but another study did not. 
 35
IMMUNE COMPLEXES 
Immune complex assays like PEG assay, Raji-cell assay, CIQ 
binding, anti C3 and conglutinin are not well standardized and they are 
still largely investigational. 
COMPLEMENT STUDIES 
CH50/C4 tends to decrease early before clinical signs of disease 
activity occur.  C3 often continues, to decline during the height of clinical 
illness.  C4 is markedly decreased than C3 in active nephritis and 
vasculitis.  Normal C3 levels are predictive of inactive renal disease. 
Acute phase reactants 
ESR very sensitive but non-specific measure of 
1. Disease activity – elevation in absence of infection denotes disease 
activity. 
2. CRP – mild persistent increase occurs in SLE with Jaccoud’s 
arthritis.  Increase more than 60 is seen in intercurrent infections and 
lupus associated serositis. 
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ALGORITHM FOR THE TREATMENT OF SLE DETERMINE 
ACTIVITY AND SEVERITY OF DISEASES 
NOT  ACTIVE 
Organ (or) 
Life Threatening 
Non Organ (or) 
Life Threatening 
Treat symptoms 
Avoid immuno suppression 
steroids NSAIDS 
Avoid immuno suppression 
ACTIVE 
Mild / Not Life 
Threatening 
Impairs quality of Life not 
organ threatening 
Severe Diseases   
Treat symptoms 
Topicals for rash 
Antimalarials 
NSAIDS Analgesics 
Treat Symptoms 
Topicals/Antimalarials 
NSAIDS Analgesics 
High dose GC (+) 
VERY SEVERE 
Cyclophosphamide 
10 – 20 mg/kg 3 – 4 
MODERATELY 
Daily PO/A2A Mycophenolate If improved 
1.5 – 2.5 mg/kg 1 – 2.5 g qd PO Less established treatment like 
Methylpred 1 gm qid for 3 days 
Plasmapharesis 
Cyclosporin 
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MATERIALS AND METHODS 
This study way conducted in 50 patients of Systemic Lupus 
Erythematosus who were attending Rheumatology Department, Medicine 
Department and Nephrology Department, Stanley Medical College 
Hospital during the period from June 2006 – July 2007. 
All the patients of Systemic Lupus Erythematosus who presented 
with varying signs and symptoms included in this study and were 
analysed clinically and laboratory wise. 
A detailed history was taken with particular emphasis on various 
organ system involvement. 
Symptoms included: 
Constitutional - Fever; Malaise; Fatigue; Weight loss  
Musculoskeletal - Pain; Swelling of joints 
Mucocutaneous - Rash; Photo sensitivity; Pruritus 
Cardio vascular - Chest pain; dyspnea; palpitations; syncope 
CNS   - Seizures; hallucinations; Abnormal behaviour;  
symptoms of peripheral neuropathy 
Renal - Hematuria 
GIT - Oral Ulcer; acute abdominal pain; abdominal Distension; 
foetal wastage 
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This was followed by detailed clinical examination. The following 
in general examination. 
♦ Photo sensitivity; Malar rash; Discoid Lupus Erythematosus 
(DLE); Purpura;  Urticaria; Erythema; Raynaud’s phenomina 
♦ Arthritis; AVN; Osteoporosis 
♦ Pericardial rub; Pleural Rub; Cardiac murmurs 
♦ Anemia; Petechiae; Lymphadenopathy 
An elaborate laboratory examination was done which include 
albumin deposits cellular carsts haemoglobin casts, tubular casts and 
urine 24 hrs urinary protein more than 500 mg/dl, Serum Creatinine 
VDRL CRP C3 C4 Antinuclear antibody.  X ray chest, ECG, Echo, USG 
Abdomen, Renal biopsy and skin biopsy in selected patients. 
For microscopic examination of urine, a clean catch early morning 
2nd voided midstream.  Urine sample while patient was still fasting were 
collected and examined in 1 – 3 hrs to avoid lysis of cell and casts and to 
ensure a reasonably concentrated and acidic urine specimen larger than 
concentrated volume of urine of about 50 ml. 
Dysmorphic erythrocyte indicate injlamatory glomerular or tubule 
interstitial disease while monomorphic RBC’s indicate lower urinary tract 
bleeding. 
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A telescopic urine sediment contains full range of cell and casts  it 
indicates global nephron involvement. 
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OBSERVATION RESULTS 
AGE DISTRIBUTION IN THIS STUDY 
NO. OF PATIENTS = 50 
AGE IN YEARS No. of patients (50) Percentage (%) 
< 15 3 6% 
15 – 20 2 4% 
21 – 25 13 26% 
26 – 30 5 10% 
31 – 35 15 30% 
36 – 40 3 6% 
41 – 45 3 6% 
46 – 50 3 6% 
> 50 2 4% 
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AVERAGE AGE OF SLE 
 
MEAN AGE 31 
MEDIAN AGE 32.5 
 
Average Age of SLE
31
32.5
MEAN AGE
MEDIAN AGE
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AGE DISTRIBUTION IN MALE / FEMALE 
Age Group Female Male 
< 15 4 2 
15 – 24 20 4 
25 – 34 38 0 
35 – 44 20 - 
45 – 54 8 - 
> 55 - 2 
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DISTRIBUTION OF CLINICAL FEATURES 
Clinical Presentation No. of Patients Percentage 
Constitutional 40 80 
Musculoskeletal 50 100 
Cutaneous 42 84 
Cardiovascular 6 12 
Renal 17 34 
Respiratory 12 24 
Psychiatry 20 40 
G IT 24 48 
Ocular 3 6 
Neurological 7 14 
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SEX DISTRIBUTION RATIO 
MALE 1 
FEMALE 9 
 
Sex Distribution Ratio
Male
Female
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DISCUSSION 
INTERPRETATION OF CLINICAL MANIFESTATION 
The study group contains 45 females and 5 males in the ratio of 
female to male 9:1. 
Age of patient in the study varied from 14-60 years. 
Mean Age is 31years. 
Highest incidence is found in the age group of 29-35 years of age. 
INITIAL PRESENTATION OF SLE 
At its onset SLE may involve one (or) more organ system. 
Overtime-additional manifestation of disease may occur. 
POLYARTHRALGIA 
Among 50 patients, 29 had initial presentation of muskulo skeletal 
system in form of arthritis myositis and arthralgia. Thus arthritis and 
arthralgia are the m/c initial manifestation in our study. During course of 
disease almost all patients develop arthralgia. 
SKIN MANIFESTATION: 
Skin manifestation as initial presentation is seen in 16 patients. 
Most common are photosensitive and malar rash seen over cheeks and 
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nose presented in 9 patients. 3 patients presented initially with discoid 
lupus erythematous. Thus skin manifestation is the second most initial 
presentation seen in our study. 
RENAL MANIFESTATION 
Among 50 patients, 5 patients presented initially with EDEMA of 
legs and Anasarca. Their 24 hr urine is in the Nephritic range. They are 
found to be lupus Nephritis on Renal biopsy. In STUDY OF ESTES and 
Christian study, Nephritis was initial presentation in 6% of cases. 
HAEMATOLOGICAL MANIFESTATION 
Hematological manifestation as initial presentation seen in 3 
Persons. 2 patients presented with Cytopenia and fever. One patient 
presented initially in form of Idiopathie thrombocytopenia. Anemis and 
Thrombocytopenia were the initial manifestation in Christian and estes et 
al studies is 2%. 
NEUROPSYCIATRY MANIFESTATION: 
Among 50 patients, 6 patients presented with neuropsyciatry 
manifestation.Seizures are the presenting manifestation in 2 patients .one 
patient presented initially with young stroke who turned out to be SLE 
vasculitis.Post parum seizure as a initial manifestation is seen in our 
patient in 8th postnatal life. She is ANA positive and Antiphospholipid 
antibody positive. 
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Thus in our study, most common initial manifestation is arthralgia. 
Percentage frequency of presenting clinical features in our study is 
compared to similar study from other parts of India [60]. 
Manifestation Northern Southern Eastern Our  Study 
Arthritis 57 86 75 58 
Skin lesions 36 48 50 32 
Nephritis 8 7.4 49 10 
Neuropsychiatry 12 35 30 12 
Thrombocytopenia 4 1.5 N.A 2 
 
Initial presentation of our study is compared to Similar Study from 
western countries [61]. 
 Our Study Toronto Europe 
Musculoskeletal 58 42 69 
Skin lesion 32 66 40 
Neuropsychiatry 12 20 12 
Renal lesion 10 42 60 
 
Western data shows higher incidence of renal lesions as initial 
manifestation compared to our study. 
CUMULATIVE PRESENTATION OF SLE 
Of 50 patients, 40 patients manifested one of constitutional 
symptoms like fever, malaise, and weight loss 
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Among 50 patients, 23 patients presented initially with 
muskuloskeletal symptoms like polyarthritis myositis muscle weakness. 
During course of time polyarthritis is seen in 45 patients and 
polyarthralgia is seen in all patients. 
In a study of Hochberg et al, the occurance of muskuloskeletal 
involvement was 83%: of them 76% showed arthritis and 5% showed 
myositis. 
The clinical feature in our study is compared to similar study in 
other parts of India. Study should m\c clinical manifestation in southern 
and northern India is polyarthritis. 
CUTANEOUS MANIFESTATION 
As far as cutaneous manifestation are concerned 41 patients should 
following manifestation. 
Manifestation No of Patients Percentage 
Malar Rash 21 42 
Photosensitivity 36 72 
Alopecia 46 92 
Discoid Rash 6 12 
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Comparison of my study to Estes at el and Hochberg et al is as 
follows. 
Manifestation Our Study Estesetal Hochberg 
Cutaneous 82 88 81 
M.Rash 44 39 61 
Photosensitivity 72 - 45 
Alopecia 92 37 45 
Discoid Rash 12 19 15 
 
Compared with western data, the incidence of Alopecia and 
photosensitivity are more common. 
The comparison of my study to similar study to other parts of 
India.60 
Manifestation N S W E Our Study 
Photosensitivity 67 52 24 NA 72 
Alopecia 82 75 53 70 92 
Skin lesion 85 74 81 90 60 
 
RENAL INVOLVEMENT 
In our study 17 patients showed evidence of renal involvement. 
 Renal involvement as initial presentation is seen in 5 patients. They 
presented as gen anasarca and their 24 hr urine protein is in the nephritic 
range. They are found to be lupus nephritis on renal biopsy. 
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In our study 15 years old boy intialy presented as cytopenia, 
During course of time he developed polyarthralgia Alopecia and gen. 
Anasarca . His 24 hr urine protein is in nephritic range and renal biopsy 
shows diffuse proliferative G.N. 
One patient presented initially with haematuria and red cell cast. 
During course of time she developed lupus nephritis. Renal biopsy 
reported as class 2 nephritis. Renal Biopsy was done in 17 patients and 
was found that D.P.G.N [class 4] Nephritis is most common histology 
seen in 7 patients. 
2 patients showed class 2 Nephritis; 2 patients showed class 3 
Nephritis: 2 patients have normal biopsy and 4 patients showed class [5] 
Membranous Nephritis. 
In male lupus diffuse proliferative glomerulo nephritis is the most 
common histology 63. 
Regarding respiratory system involvement 12 patients showed 
pulmonary manifestation in form of PLEURAL Effusion [B/L] (or) 
unilateral in 6 patients [12%]. Intertitial pneumonitis in 1 patient [2%] 
and pneumonic consolidation in 5 patients [10%]. 
In Estes et al study occurrence of lupus pneumonitis was 9% 
fibrosis was 6%.  
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About 6 patients showed evidence of cardiovascular involvement. 
5 of them presented with valvular abnormality with mild pulmonary 
hypertension. One patient had Libman Sac Endocarditis. 
CNS Manifestation 
About 27 patients [54%] showed evidence of CNS involvement in 
the form of seizure 4 patients [8%]; peripheral motor neuropathy 2 
patients [4%]; young stroke in 1 patients [2%] and neuropsychiatry 
manifestation in the form of insomnia and depression in 21 patients. 
Headache is presented in 19 patients. 
The comparative study of neuropsychiatry manifestation in this 
study to estes et al and Hochberg et al as follows. 
Manifestation Our Study Estes et al Hochberg et al 
CNS 54% 59 55 
GTCS 8% 13 26 
Peripheral Neuropathy 4% 7 21 
Stroke 2% - 5 
Neuropsychiatry 42% 37 16 
 
Vasculitis lesion at tip of digit may result in gangrene. 4 patients 
presented with gangrene of toes and fingers. 
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GIT INVOLVEMENT 
In this study 24 patients [48%] showed evidence of GIT 
involvement in form of nausea vomiting and dyspepsia. According to 
Hochberg et al this may represent low-grade peritoneal inflammation (or) 
vascular disease of bowel (or) related to medication. 
Oral ulcer is seen in 38 patients [76%]. 
USG evidence of hepatosplenomegaly and lymphadenopathy is 
seen in 10 patients [20%]. 
2 patients presented with Acute Cholecystitis. 
Eye manifestation in form of  R Eye Retinal Vasculitis and CRAO 
is seen in 2 patients. 
Frequency of laboratory abnormalities in SLE 
As far as laboratory profile is concerned following results are 
observed. 
37 patients blood report revealed anemias [74%]. Most of them are 
normocytic normochromic anemias. 1 patient presented with hemolytic 
anemia another patient presented with recurrent anemia and fever. 
Leucopenia generally range from 2600 cells and 4000 cells/mm3 
and is often associated with active disease. 5 patients had leucopenis 
[10%]. 
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Thrombocytopenia 
4 patients had thrombocytopenia [8%]. One patient presented 
initially with idiopathic thrombocytopenia. 
Pancytopenia 
            Is seen in 3 patients.  
ESR was found to be raised in all of the patient but with a 
significant rise in patients with infection disease flare and vasculitis. 
Serological examination of A.N.A showed positive in all 50 
patients. The patient was 70% homogenous and 30% peripheral rim 
pattern. 
Anti ds DNA examination by farr assay revealed positive in 24 
patients [48%]. 
Anticardiolipid andibody is associated with increased risk of 
seizure63. 
Frequency of laboratory abnormality in SLE of our study is 
compared to similar study in other parts of India60 
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Abnormality Northern Sourthern Our Study 
Anaemia 38 52 74 
Thrombocytopenia 10 7.5 8 
Leucopenia 16 12.4 10 
Non Nephrotic 45 40 20 
Nephrotic 8 5 12 
ANA 98 96 100 
Anti ds DNA 55 60 48 
 
According to Hochberg et al ESR was found to be raised in all 
patients but significant rise is found in patients with disease flare and 
vasculitis. 
According to Hochberg et al patient with mesangial nephritis have 
small amount of proteinuria [< 1 gm/dl]. Pt with membranous 
nephropathy have proteinuria often at nephritic range. Patient with 
proliferative nephritic have hypertension, nephritic urine sediment 
,various degree of proteinuria., high titre of anti ds DNA antibodies are 
found in-patient with proliferative nephritis. 
Mortality and Morbidity 
Mortality was seen in 3 patients during the study. 
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Lupus Nephritis 2 Patients 
Dvt/pulmonary embolism 1 Patient 
 
According to one study early deaths are caused by active disease 
infection n and nephitis are major cause of mortality in all stages of 
SLE.64 
According to Hochberg et al 10% patients of systemic lupus may 
demonstrate acute thromboplebitis as a feature of their illness either as a 
manifestation of lupus vasculitis (or) a/w cirrculating anticogulant . 
previous venous inflammation give rise to secondary thrombosis followed 
by multiple pulmonary embolism. 
A Europian study of 1000 patients with SLE demonstrated 10 years 
survival probably of 92% reduced to 88% presented with nephropathy . 
mean age of death was 44 varies widely from 18.-81 years .cause of death 
varies . Renal lupus is the biggest number of death in those with less than 
5 years of disease where as vascular disease was the most common factor 
who died later in the disease.65 
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CONCLUSION 
¾ Mean Age of SLE is 31 years. 
¾ Highest Incidence is found in age group of 29-35 years of age. 
¾ The most common clinical presentation in our study is 
muskuloskeletal involvement seen in 90%. 
¾ Next most common presentation is skin lesions seen in 82%. 
¾ Neuropsychiatry manifestation seen in 54% 
¾ Renal involvement is seen in 34% 
¾ GIT involvement is seen in 48% 
¾ Most common initial presentation in our study is musculoskeletal 
involvement similar to the western data. Incidence of renal lesion 
as initial presentation in western data is more compared to my 
study. 
¾ Normocytic nonmochromic anemias was the most common 
presentation leucopenia 10% ; thrombocytopenia 8% as far as 
haematological manfestation are concerned. 
¾ ANA was positive in all patients. 
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¾ Anti ds DNA is seen in 48%. Anti  ds DNA is seen in  all patients 
with lupus nephrits compared to vascular lesions. 
¾ Renal biopsy revealed active renal disease and evidence of diffuse 
proliferate glomerulonephrtis seen in 7 patient. Patients with 
DPGN have nephritic range proteinuria hypertension ds DNA. 
Membranous nephropathy have nephrotic range proteinuria. 
¾ ESR raised in almost all patients with SLE. But significant increase 
is seen in vasculitis and active lesions. 
¾ Death is seen in 3 patients during the course of study. 2 of them 
died of lupus nephritis and 1 patient died of vascular cause. 
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PROFORMA 
 
PARTICULARS OF THE PATIENT 
 
1.   Name        :   
2.   Age            :    
3.   Sex             : 
4.   Occupation   : 
5.   Hospital No. : 
6. Address      : 
 
Chief Complaints: 
 
HISTORY OF PRESENTING COMPLAINTS: 
 
Systemic       Y/N 
Fatigue       Y/N 
Malaise       Y/N 
Fever       Y/N 
Anorexia       Y/N 
Weight loss       Y/N 
Musculo Skeletal      Y/N 
Arthalgia       Y/N 
Myalgia       Y/N 
Hand deformity      Y/N 
Cutaneous       Y/N 
Photosensitivity      Y/N 
Malar Rash       Y/N 
Oral Ulcers       Y/N 
Alopecia       Y/N 
 
 
RENAL MANIFESTATIONS: 
 
Edema       Y/N 
Haematuria       Y/N 
NERVOUS SYSTEM: 
 
Cognitive Dysfunction     Y/N 
Memory       Y/N 
Headache       Y/N 
Seizure       Y/N 
Psychosis       Y/N 
Stroke       Y/N 
HAEMATOLOGICAL: 
 
Easy fatigability      Y/N 
Lymphadenopathy     Y/N 
CARDIAC MANIFESTATIONS: 
 
Chest pain       Y/N 
Palpitation       Y/N 
PULMONARY MANIFESTATIONS: 
 
Dyspnoea       Y/N 
 
GASTROINTESTINAL MANIFESTATIONS: 
 
Nausea       Y/N 
Vomiting       Y/N 
Abdominal pain      Y/N 
Distention       Y/N 
Obstruction       Y/N 
 
PAST HISTORY:        
Hypertension      Y/N 
Diabetes Mellitus      Y/N 
Tuberculosis      Y/N 
Bronchial Asthma      Y/N 
Chronic Obstructive Pulmonary Diseases  Y/N 
Heart disease      /N 
Kidney Disease      Y/N 
Seizure       Y/N 
Recurrent Abortions     Y/N 
C.V.A.       Y/N 
PERSONAL HISTORY:      
 
SMOKING       Y/N   
ALCOHOL       Y/N 
Tobacco        Y/N 
Premarital contact      Y/N 
Extra marital contact     Y/N 
FAMILY HISTORY: 
 
CLINICAL EXAMINATION 
 
♦ Conscious 
♦ Oriented 
♦ Temperature 
♦ Anemia 
♦ Clubbing 
♦ Pedal Edema 
♦ Icterus 
 
Lymphadenopathy 
 
♦ Pulse : 
 
♦ B.P.   : 
 
♦ R.R.   : 
 
♦ Cutaneous 
 
♦ Malar Rash 
 
♦ Oral Ulcer 
 
♦ Alopecia 
 
♦ Photo sensitivity Rash 
 
♦ Hand deformity  
 
C.V.S. 
 
♦ S1 
♦ S2 
♦ Murmur 
♦ Pericardial Rub 
R.S. 
♦ N.V.B.S. 
♦ Added sounds 
♦ Crackles 
♦ Rhonchi 
♦ Pleural rub 
♦ Breath sound 
 
P/A 
♦ Soft 
♦ Tenderness 
♦ Hepatomegaly 
♦ Splenomegaly 
 
C.N.S. 
              FND 
INVESTIGATIONS: 
 
URINE ROUTINE EXAMINATION 
 
♦ Albumin 
♦ Sugar 
♦ Deposits 
24 hours urine protein  
1. TC     : 
2. DC     :  
3. ESR      : 
4. Haemoglobin    : 
5. Peripheral Blood smear study : 
6. Blood sugar    : 
7. Blood urea    : 
8. Serum Creatinine   : 
9. LFT     : 
10. RA Factor    : 
11. ANA      : 
12. Pulmonary Function Test  : 
13. Anti DS DNA   : 
14. X ray chest PA view  : 
15. CT Chest    : 
16. ECG     : 
17. Echo     : 
 
 
 ETHICAL COMMITTEE  CLEARANCE 
 
 

 
